Skip to content
Use caution Drug recall · FDA · Published January 23, 2015

Mylan Recalls Nicardipine Hydrochloride Injection Due to Subpotency

Mylan Institutional LLC recalls specific lots of Nicardipine Hydrochloride Injection due to subpotent drug and failed impurity specifications.

🇺🇸 FDA recall #D-0413-2015DrugMylan Institutional ›
Take action

Contact the company

Recalling firmMylan Institutional LLC4901 Hiawatha Dr · Rockford, IL 61103-1287
✎ GovInfoNow plain-language explainer

Mylan Institutional LLC is recalling Nicardipine Hydrochloride Injection, 25 mg/10 ml (2.5 mg/mL), 10 mL single dose vials manufactured in India. The recall addresses issues where the drug may be subpotent or fail impurities and degradation specifications. This affects specific lots with expiration dates of February 2015 and April 2015. Read more at govinfonow.com/recall/45017-mylan-institutional-llc-recalls-nicardipine-hydrochloride-injection-25-mg-10.

Source Summary by GovInfoNow · govinfonow.com/recall/45017-mylan-institutional-llc-recalls-nicardipine-hydrochloride-injection-25-mg-10 · Updated October 12, 2026 · FDA enforcement record: FDA #D-0413-2015

Cite this page

“Mylan Recalls Nicardipine Hydrochloride Injection Due to Subpotency.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/45017-mylan-institutional-llc-recalls-nicardipine-hydrochloride-injection-25-mg-10. Based on FDA recall #D-0413-2015 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0413-2015%22&limit=1).

The FDA announced on Jan. 23, 2015, that Mylan Institutional LLC voluntarily recalled Nicardipine Hydrochloride Injection due to subpotency and failed impurity specifications. The recall affects 78,090 vials distributed nationwide.

How to tell if you have it

  • Brand: Mylan Institutional
  • Product: Nicardipine Hydrochloride Injection, 25 mg/10 ml (2.5 mg/mL), 10 mL single dose vial
  • NDC: 67457-224-10
  • Lot codes: UW301, UW302 (Exp 02/15); UW303, UW304, UW305, UW306 (Exp 04/15)
  • Quantity: 78,090 vials
  • Distribution: Nationwide

The hazard

The product is classified as a subpotent drug and failed impurities/degradation specifications. The FDA classified the recall as Class III.

Context

GovInfoNow's records show Mylan Institutional LLC has had 10 other recalls since Feb. 11, 2015. Recent labeling issues include a May 3, 2021 recall for incorrect lot/exp dates on Thiamine HCl Injection and an Aug. 17, 2020 recall involving label mix-ups with Amiodarone Injection. Other recent recalls of similar products include Mylan Prasugrel Tablets Recall (Aug. 17, 2026), Mylan Mycophenolate Mofetil Injection Recall (July 2, 2026), and Mylan Recalls Amnesteem Isotretinoin Capsules Due to Dissolution Failure (Feb. 24, 2026).

How to tell if you have this one

Check for Nicardipine Hydrochloride Injection, 25 mg/10 ml (2.5 mg/mL), 10 mL single dose vials with NDC 67457-224-10. Affected lots are UW301, UW302 (Exp 02/15) and UW303, UW304, UW305, UW306 (Exp 04/15). The product was manufactured in India for Mylan Institutional LLC.

  • Brand
    Mylan Institutional
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Identify Affected Lots

    Check inventory for NDC 67457-224-10 and lots UW301, UW302, UW303, UW304, UW305, or UW306.

  2. Consult Manufacturer

    Contact Mylan Institutional LLC for specific return or disposal instructions as the remedy is not explicitly detailed in this record.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 15 months after the firm started it.

1. Firm started the recall: Jan 23, 201512. FDA classified it Class III: Mar 16, 201523. Published in FDA’s Enforcement Report: Mar 25, 201534. FDA terminated the recall: Apr 11, 2016420152016
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0413-2015 (January 23, 2015) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0413-2015 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA